Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Calcific aortic valve disease augments vesicular microRNA-145-5p to regulate the calcification of valvular interstitial cells via cellular crosstalk.

Basic research in cardiology·2025
Same author

Coronary intravascular lithotripsy and rotational atherectomy for severely calcified stenosis: Results from the ROTA.shock trial.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2023
Same author

Sleep-disordered breathing and lung function abnormalities in adults with congenital heart disease.

Sleep & breathing = Schlaf & Atmung·2023
Same author

Human and porcine aortic valve endothelial and interstitial cell isolation and characterization.

Frontiers in cardiovascular medicine·2023
Same author

Overlapping obstructive sleep apnea and chronic obstructive pulmonary disease in patients undergoing percutaneous coronary intervention.

Clinical research in cardiology : official journal of the German Cardiac Society·2023
Same author

Transcatheter valve repair of tricuspid regurgitation with the PASCAL system: TriCLASP study 30-day results.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2022

Video Experimental Relacionado

Updated: Jul 20, 2026

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

Función y densidad desregulada del receptor AT1 sensible a estatinas en hombres con hipercolesterolemia.

G Nickenig1, A T Bäumer, Y Temur

  • 1Klinik III für Innere Medizin, Universität Köln, Germany. georg.nickenig@uni-koeln.de

Circulation
|November 26, 1999
PubMed
Resumen

El colesterol alto en los hombres aumenta la expresión del receptor de angiotensina II tipo 1 y la respuesta a la presión arterial. Las estatinas reducen efectivamente la expresión de este receptor y mejoran la presión arterial, ofreciendo nuevas vías terapéuticas.

Más Videos Relacionados

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Videos de Experimentos Relacionados

Last Updated: Jul 20, 2026

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Área de la Ciencia:

  • Ciencias Cardiovasculares Ciencias Cardiovasculares
  • Endocrinología Endocrinología.
  • Farmacología Farmacología.

Sus antecedentes:

  • La hipercolesterolemia está relacionada con el aumento de la expresión vascular del receptor de angiotensina II tipo 1 (AT1).
  • Investigaciones anteriores mostraron este efecto en cultivos celulares y modelos animales.

Objetivo del estudio:

  • Para investigar la sobreexpresión del receptor AT1 en hombres con hipercolesterolemia.
  • Evaluar los efectos terapéuticos de los inhibidores de la HMG CoA reductasa (estatinas) en la expresión y función del receptor AT1.

Principales métodos:

  • Respuesta evaluada de la presión arterial a la infusión de angiotensina II en hombres con normocolesterolemia e hipercolesterolemia.
  • Medición de la expresión del receptor AT1 en plaquetas aisladas.
  • Pacientes evaluados antes y después de la terapia con estatinas.

Principales resultados:

  • La hipercolesterolemia aumentó significativamente la elevación de la presión arterial inducida por la angiotensina II.
  • La expresión del receptor AT1 fue significativamente mayor en individuos con hipercolesterolemia.
  • El tratamiento con estatinas revirtió la respuesta elevada a la presión arterial y reguló a la baja la densidad del receptor AT1.

Conclusiones:

  • La hipercolesterolemia induce la sobreexpresión del receptor AT1 y mejora los efectos de la angiotensina II en los hombres.
  • Los hallazgos ofrecen información sobre la patogénesis de la hipertensión y la aterosclerosis.
  • Sugiere potencial para nuevas estrategias terapéuticas dirigidas a los receptores AT1.